1. Home
  2. COLL vs SHCO Comparison

COLL vs SHCO Comparison

Compare COLL & SHCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COLL
  • SHCO
  • Stock Information
  • Founded
  • COLL 2002
  • SHCO 1995
  • Country
  • COLL United States
  • SHCO United Kingdom
  • Employees
  • COLL N/A
  • SHCO N/A
  • Industry
  • COLL Biotechnology: Pharmaceutical Preparations
  • SHCO Hotels/Resorts
  • Sector
  • COLL Health Care
  • SHCO Consumer Discretionary
  • Exchange
  • COLL Nasdaq
  • SHCO Nasdaq
  • Market Cap
  • COLL 958.8M
  • SHCO 1.0B
  • IPO Year
  • COLL 2015
  • SHCO 2021
  • Fundamental
  • Price
  • COLL $31.60
  • SHCO $6.88
  • Analyst Decision
  • COLL Strong Buy
  • SHCO Buy
  • Analyst Count
  • COLL 4
  • SHCO 2
  • Target Price
  • COLL $43.75
  • SHCO $7.25
  • AVG Volume (30 Days)
  • COLL 291.1K
  • SHCO 287.6K
  • Earning Date
  • COLL 08-07-2025
  • SHCO 08-08-2025
  • Dividend Yield
  • COLL N/A
  • SHCO N/A
  • EPS Growth
  • COLL N/A
  • SHCO N/A
  • EPS
  • COLL 1.25
  • SHCO N/A
  • Revenue
  • COLL $664,283,000.00
  • SHCO $1,224,734,000.00
  • Revenue This Year
  • COLL $20.23
  • SHCO $8.99
  • Revenue Next Year
  • COLL $3.82
  • SHCO $6.02
  • P/E Ratio
  • COLL $25.23
  • SHCO N/A
  • Revenue Growth
  • COLL 17.17
  • SHCO 8.21
  • 52 Week Low
  • COLL $23.23
  • SHCO $4.43
  • 52 Week High
  • COLL $42.29
  • SHCO $8.47
  • Technical
  • Relative Strength Index (RSI)
  • COLL 61.58
  • SHCO 44.97
  • Support Level
  • COLL $31.53
  • SHCO $7.41
  • Resistance Level
  • COLL $32.95
  • SHCO $7.48
  • Average True Range (ATR)
  • COLL 0.88
  • SHCO 0.27
  • MACD
  • COLL 0.06
  • SHCO -0.12
  • Stochastic Oscillator
  • COLL 73.51
  • SHCO 17.98

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

About SHCO Soho House & Co Inc.

Soho House & Co Inc is a membership platform of physical and digital spaces that connects a vibrant, diverse group of members from across the world. The members use the platform to work, socialize, connect, create, and flourish all over the world. It offers lease agreements for Houses, hotels, restaurants, studios, spas, and other properties. The company's reportable segments are: United Kingdom; The Americas; and Europe and Rest of the world. The majority of its revenue is generated from the Americas segment, which encompasses its operating units in the Americas, including Soho Houses, stand-alone U.S. restaurants, Soho Friends, and the management fees under a hotel management contract for the operation of The Ned London.

Share on Social Networks: